Study (site) | N | Number of events (RC/NI/IND) | Day | Drug | \(\hat{F}_{KM} \left( t \right)\) estimate of recrudescence [95% confidence interval] | \(\hat{F}_{CIF} \left( t \right)\) estimate of recrudescence [95% confidence interval] |
---|---|---|---|---|---|---|
10% thresholda | ||||||
Nikiema-2010 (Burkina Faso, Gourcy)b | 144 | 12/28/3 | 28 | AL | 10.3 [4.8–15.8] | 9.4 [4.3–14.5] |
The 4ABC Trial (Burkina Faso, Nanoro) [18] | 294 | 24/142/9 | 28 | AL | 11.1 [6.8–15.4] | 8.6 [5.3–11.8] |
Sirima-2015 (Burkina Faso, Balonghin) [21] | 66 | 31/5/0 | 63 | ASMQ | 11.5 [7.2–15.9] | 8.1 [1.2–14.9] |
5% thresholda | ||||||
Yeka-2008 (Uganda, Kanungu) [45] | 199 | 9/49/6 | 42 | AL | 5.2 [1.9–8.5] | 4.6 [1.7–7.6] |
Sirima-2015 (Tanzania, Korogwe) [21] | 27 | 1/3/2 | 63 | AL | 5.0 [0.0–14.6] | 4.3 [0.0–12.9] |
Schramm-2013 (Liberia, Nimba) [46] | 145 | 7/45/6 | 42 | AL | 5.6 [1.5–9.7] | 5.0 [1.4–8.6] |
Agrawal-2013 (Kenya, Siaya) [47] | 136 | 5/48/12 | 42 | AL | 5.2 [0.5–10.0] | 4.2 [0.6–7.8] |
Karunajeewa-2008 (PNG, Madang) [48] | 54 | 2/20/0 | 42 | AL | 5.9 [0.0–14.3] | 4.7 [0.0–11.3] |
Sirima-2015 (Kenya, Kisumu) [21] | 99 | 4/23/9 | 63 | ASMQ | 6.1 [0.1–12.0] | 4.8 [0.2–9.4] |
Sirima-2015 (Burkina Faso, Balonghin) [21] | 128 | 5/58/1 | 63 | AL | 5.4 [0.7–10.2] | 4.0 [0.6–7.5] |
Bukirwa-2006 (Uganda, Tororo) [49] | 204 | 10/89/2 | 28 | AL | 6.6 [2.6–10.7] | 4.9 [2.0–8.0] |
Sirima-2015 (Kenya, Ahero) [21] | 73 | 3/28/10 | 63 | ASMQ | 7.8 [0.0–16.7] | 4.7[0.0–10.0] |